Modulation of Extravascular Binding of Recombinant Factor IX Impacts the Duration of Efficacy in Mouse Models

Abstract

Background There is an emerging concept that in addition to circulating coagulation factor IX (FIX), extravascular FIX contributes to hemostasis.

Objective Our objective was to evaluate the efficacy of extravascular FIX using animal models of tail clip bleeding and ferric chloride-induced thrombosis.

Methods Mutant rFIX proteins with described enhanced (rFIX_K5R) or reduced (rFIX_K5A) binding to extracellular matrix were generated and characterized using in vitro aPTT, one-stage clotting, and modified FX assays. Using hemophilia B mice, pharmacokinetic (PK) parameters and in vivo efficacy of these proteins were compared against rFIX wild-type protein (rFIX_WT) in a tail clip bleeding and FeCl₃-induced thrombosis model. Respective tissue disposition of FIX was evaluated using immunofluorescence.

Results In vitro characterization demonstrated comparable clotting activity of rFIX proteins. The PK profile showed that rFIX_K5A displayed the highest plasma exposure compared to rFIX_WT and rFIX_K5R. Immunofluorescence evaluation of liver tissue showed that rFIX_K5R was detectable up to 24 hours, whereas rFIX_WT and rFIX_K5A were detectable only up to 15 minutes. In the tail clip bleeding model, rFIX_K5R displayed significant hemostatic protection against bleeding incidence for up to 72 hours postintravenous administration of 50 IU/kg, whereas the efficacy of rFIX_K5A was already reduced at 24 hours. Similarly, in the mesenteric artery thrombus model, rFIX_K5R and rFIX_WT demonstrated prolonged efficacy compared to rFIX_K5A.

Conclusion Using two different in vivo models of hemostasis and thrombosis, we demonstrate that mutated rFIX protein with enhanced binding (rFIX_K5R) to extravascular space confers prolonged hemostatic efficacy in vivo despite lower plasma exposure, whereas rFIX_K5A rapidly lost its efficacy despite higher plasma exposure.

Keywords

Hemophilia B mice - Coagulation Factor IX - extravascular Factor IX - hemostatic efficacy - tail clip bleeding model - ferric chloride-induced thrombosis

Authors' Contribution

The manuscript has been read and approved for submission by all authors. S.K.M., H.P., M.M., P.C., S.P., and P.P. contributed to the design and/or implementation of the research, to the analysis of the results and to the writing of the manuscript. M.M. performed the pharmacokinetic evaluations. T.K. planned and carried out SPR experiments. E.H., M.B., M.W.N., and M.B. provided critical feedback and helped shape the final manuscript.

^* Authors contributed equally.

Publikationsverlauf

Eingereicht: 08. Juli 2022

Angenommen: 11. Januar 2023

Accepted Manuscript online:
10. Mai 2023

Artikel online veröffentlicht:
08. Juni 2023

• References

• 1 National Hemophilia Foundation. “MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding).”. 2016
• 2 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (03) 560-560
• 3 Kleiboer B, Nielsen B, Ma AD, Abajas Y, Monroe DM, Key NS. Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: a single centre case series. Haemophilia 2020; 26 (01) e23-e25
• 4 Malec LM, Croteau SE, Callaghan M, Matino D, Friedman KD, Sidonio RF. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US and Canadian hemophilia treatment centers. Blood 2019; 134: 2407-2407
• 5 Kitchen S, Preston FE. Quality in Laboratory Hemostasis and Thrombosis. 2nd ed. 2013: 105-114
• 6 Cooley B, Broze Jr GJ, Mann DM, Lin F-C, Pedersen LG, Stafford DW. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood 2019; 133 (22) 2445-2451
• 7 Cooley B, Funkhouser W, Monroe D. et al. Prophylactic efficacy of BeneFIX vs alprolix in hemophilia B mice. Blood 2016; 128 (02) 286-292
• 8 Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci U S A 1983; 80 (13) 4119-4123
• 9 Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun 1983; 111 (02) 723-731
• 10 Stern DM, Knitter G, Kisiel W, Nawroth PP. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol 1987; 66 (02) 227-232
• 11 Cheung WF, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992; 267 (29) 20529-20531
• 12 Cheung WF, van den Born J, Kühn K, Kjellén L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A 1996; 93 (20) 11068-11073
• 13 Horn C, Négrier C, Kalina U, Seifert W, Friedman KD. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost 2019; 17 (01) 138-148
• 14 van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256 (07) 3433-3442
• 15 Marlar RA, Strandberg K, Shima M, Adcock DM. Clinical utility and impact of the use of the chromogenic vs. one-stage factor activity assays in haemophilia A and B. Eur J Haematol 2020; 104 (01) 3-14
• 16 Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight 2019; 5 (14) 4
• 17 Li L, Vorobyov I, Allen TW. The different interactions of lysine and arginine side chains with lipid membranes. J Phys Chem B 2013; 117 (40) 11906-11920
• 18 Gui T, Lin H-F, Jin D-Y. et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100 (01) 153-158
• 19 Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 1997; 272 (27) 16717-16720
• 20 Stafford DW. Extravascular FIX and coagulation. Thromb J 2016; 14 (Suppl. 01) 35
• 21 Gui T, Reheman A, Ni H. et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 2009; 7 (11) 1843-1851